BioNano Genomics Inc (BNGO)

Sector:
HEALTH CARE
Industry:
HEALTH CARE SUPPLIES
SIC:
LABORATORY ANALYTICAL INSTRUMENTS
CEO:
Dr. Robert Erik Holmlin
Employees:
77
9540 TOWNE CENTRE DRIVE SUITE 100 SAN DIEGO CA 92121
(858) 888-7600

Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space.

Data derived from most recent annual or quarterly report
Market Cap 1.157 Billion Shares Outstanding153.186 Million Avg 30-day Volume 42.601 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.07
Price to Revenue48.1588 Debt to Equity0.0 EBITDA-72.015 Million
Price to Book Value2.5687 Operating Margin-428.7915 Enterprise Value615.331 Million
Current Ratio12.473 EPS Growth0.333 Quick Ratio11.701
1 Yr BETA 1.9844 52-week High/Low 0.0 / Profit Margin-402.8419
Operating Cash Flow Growth-87.7303 Altman Z-Score12.378 Free Cash Flow to Firm -127.519 Million
View SEC Filings from BNGO instead.

View recent insider trading info

Funds Holding BNGO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BNGO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BARKER DAVID L

  • Director
40,751 2021-08-17 2

TWOMEY CHRISTOPHER J

  • Director
40,751 2021-08-17 2

VUORI KRISTIINA MD

  • Director
40,751 2021-08-17 2

LUDERER ALBERT

  • Director
40,751 2021-08-17 2

MAMUSZKA HANNAH

  • Director
40,751 2021-08-17 2

LINNEY YVONNE

  • Director
40,751 2021-08-17 2

SHIPPY RICHARD CHIEF BUSINESS OFFICER

  • Officer
400,000 2021-06-15 2

PRIAR ROBERT J CHIEF COMMERCIAL OFFICER

  • Officer
400,000 2021-06-01 2

STEWART CHRISTOPHER P. CHIEF FINANCIAL OFFICER

  • Officer
233,000 2021-05-26 1

HOLMLIN R. ERIK PRESIDENT AND CEO

  • Officer
  • Director
585,191 2021-05-12 0

OLDAKOWSKI MARK CHIEF OPERATING OFFICER

  • Officer
252,086 2021-05-12 0

CHAUBEY ALKA CHIEF MEDICAL OFFICER

  • Officer
275,000 2021-04-01 0

ROBINSON WARREN CHIEF COMMERCIAL OFFICER

  • Officer
0 2020-02-18 0

ADAMS HEATHER CHIEF ADMINISTRATIVE OFFICER

  • Officer
0 2020-02-18 0

CAI DARREN

  • Director
0 2019-06-06 0

ZHOU QUAN

  • Director
  • 10% Owner
0 2019-06-06 0

WANG JUNFENG

  • Director
  • 10% Owner
0 2019-06-06 0

WARD MICHAEL JAMES FORMER CHIEF FINANCIAL OFFICER

  • Officer
0 2019-03-01 0

BORODKIN MARK CHIEF OPERATING OFFICER

BORODKIN MARK CHIEF OPERATING OFFICER

  • Officer
6,815 2019-01-18 0

DP VIII ASSOCIATES, L.P.

BLAIR JAMES C

DOVEY BRIAN H

TREU JESSE I

VITULLO NICOLE

HALAK BRIAN K

  • 10% Owner
6,891 2018-08-23 0

LC FUND VI, L.P.

LC PARALLEL FUND VI, L.P.

ROSY SHINE LTD

  • 10% Owner
2,906,915 2018-08-23 0

CAO HAN PHD CHIEF SCIENTIFIC OFFICER

  • Officer
112,936 2018-08-23 0

ROSY SHINE LTD

  • 10% Owner
1,134,000 2018-08-23 0

DOMAIN PARTNERS VIII, L.P.

BLAIR JAMES C

DOVEY BRIAN H

TREU JESSE I

VITULLO NICOLE

HALAK BRIAN K

  • 10% Owner
0 2018-08-21 0

DOMAIN ASSOCIATES

BLAIR JAMES C

DOVEY BRIAN H

VITULLO NICOLE

HALAK BRIAN K

KAMDAR KIM P.

  • 10% Owner
140 2018-08-21 0

LC FUND VI, L.P.

LC HEALTHCARE FUND I, L.P.

LC PARALLEL FUND VI, L.P.

  • 10% Owner
0 2018-08-21 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments